Arrowstreet Capital’s Pactiv Evergreen Inc. Common stock PTVE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-109,849
Closed -$1.98M 2138
2025
Q1
$1.98M Buy
109,849
+34,111
+45% +$606K ﹤0.01% 1299
2024
Q4
$1.32M Sell
75,738
-491,942
-87% -$6.65M ﹤0.01% 1387
2024
Q3
$6.53M Sell
567,680
-218,958
-28% -$2.51M 0.01% 884
2024
Q2
$8.9M Sell
786,638
-167,637
-18% -$2.23M 0.01% 676
2024
Q1
$13.7M Buy
954,275
+759,395
+390% +$10.8M 0.01% 597
2023
Q4
$2.67M Buy
+194,880
New +$2.05M ﹤0.01% 900
2023
Q2
Sell
-125,882
Closed -$1.01M 1521
2023
Q1
$1.01M Sell
125,882
-27,646
-18% -$284K ﹤0.01% 1063
2022
Q4
$1.74M Sell
153,528
-2,930
-2% -$32K ﹤0.01% 905
2022
Q3
$1.37M Buy
156,458
+140,242
+865% +$1.46M ﹤0.01% 942
2022
Q2
$162K Buy
+16,216
New +$163K ﹤0.01% 1176
2021
Q3
Sell
-145,409
Closed -$2.19M 1919
2021
Q2
$2.19M Sell
145,409
-386,200
-73% -$5.8M ﹤0.01% 1323
2021
Q1
$7.3M Buy
531,609
+69,036
+15% +$1.07M 0.01% 1004
2020
Q4
$8.39M Buy
+462,573
New +$7.14M 0.01% 953

Arrowstreet Capital's PTVE Position: Q2 2025 in Review

Arrowstreet Capital sold out of Pactiv Evergreen Inc. Common stock (PTVE) in Q2 2025, closing a stake of 109,849 shares — an estimated $1.98M sold.

Arrowstreet Capital first reported a position in PTVE in Q4 2020 and held it in 13 quarters. The position peaked at $13.7M in Q1 2024. 0 funds tracked by Wall St. Rank hold PTVE as of Q2 2025.

  • Arrowstreet Capital reported no remaining Pactiv Evergreen Inc. Common stock position as of Q2 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 109,849 Pactiv Evergreen Inc. Common stock shares in Q2 2025, an estimated $1.98M.
  • Arrowstreet Capital first reported a position in Pactiv Evergreen Inc. Common stock in Q4 2020 and held it in 13 quarters.
  • Arrowstreet Capital's Pactiv Evergreen Inc. Common stock position peaked at $13.7M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Pactiv Evergreen Inc. Common stock as of Q2 2025.

Based on Arrowstreet Capital's 13F filing for Q2 2025, filed 13 Aug 2025.